Every country leader eventually gets the letter.
The committee has reviewed the product, and it will not be listed. Or reimbursement has been refused.
On that day it feels final. The forecast is wrong, the team is waiting, and headquarters wants to know what happened.
In my experience, it is rarely the end. It is the start of a slower and more honest plan.
The steps I have come to follow:
Understand the decision. Ask formally what evidence or value the committee found missing. Read the reasons before reacting.
Rebuild the case with medical. Could new data, or a narrower patient group, answer the concern? Resubmit only when something has truly changed. Sending the same file again only spends credibility.
Focus where patients have access. Move effort to the accounts and channels where the product is listed. Effort should follow access, not hope.
Reset the plan openly. Update the forecast, the team and headquarters honestly. A late surprise always costs more than a lower number.
What I try never to do is blame the committee, or look for a way around the process. The same people will review the next submission, and the one after that.
“A refusal is feedback on the case, not a verdict on the brand.”
Lesson 17 of 17 in Step 4: Distributors and market access, with the full guide and a checklist for this week.